Benzinga | Jul 20, 2021 04:10PM EDT

Prothena To Present Data From Two Of Its Alzheimer's Disease Programs At Alzheimer's Association International Conference 2021 Jul. 26

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that it will present preclinical data on two of its Alzheimer's disease (AD) programs at the Alzheimer's Association International Conference(r) 2021 (AAIC(r)), to be held online and in-person July 26-30, 2021. The two presentations will focus on data for PRX012, Prothena's next-generation anti-amyloid beta (A?) antibody being developed for subcutaneous administration for patients with AD, as well as data on the company's dual A?-tau vaccine being developed for the prevention and treatment of AD.

PRX0012: Next-generation, high-potency A? antibody for Alzheimer's disease with best-in-class potential

PRX012 is a next-generation, high-potency monoclonal antibody designed to deliver best-in-class efficacy, safety and patient experience for the treatment of AD. PRX012 binds to the N-terminus of A?, a key component of the plaques associated with AD. The PRX012 Investigational New Drug Application (IND) is expected in 1Q 2022. Data to be presented at AAIC will describe the ability of PRX012 to mediate microglial phagocytic clearance of both unmodified A? and pyroglutamate-modified A?pE3-42, in plaques of human AD brain tissue ex vivo.

* Poster # 57773, available to view starting Monday July 26, 2021

* Presenting Author: Wagner Zago, PhD, Chief Scientific Officer

Dual A?-tau vaccine for Alzheimer's disease

Prothena's multi-epitope vaccine, is a single agent designed to prevent the two key processes associated with AD: formation of A? plaques and intraneuronal tau tangles. Both A? and tau are considered main factors underlying the disease development and progression of AD. While the majority of vaccines and passive immunotherapies currently under development target one of these components, Prothena's vaccine was designed to target both A? and tau simultaneously. Preclinical data to be presented at AAIC will describe the generation of appropriate antibody quantities, phagocytosis of A?, and blockade of tau binding to heparan-sulfate analog, a surrogate endpoint for neuronal uptake of tau by various vaccine constructs.

* Poster # 52980, available to view starting Monday July 26, 2021

* Presenting Author: Robin Barbour, Sr. Director, Antibody and Assay Development